WO2008068429A3 - Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12 - Google Patents

Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12 Download PDF

Info

Publication number
WO2008068429A3
WO2008068429A3 PCT/FR2007/001898 FR2007001898W WO2008068429A3 WO 2008068429 A3 WO2008068429 A3 WO 2008068429A3 FR 2007001898 W FR2007001898 W FR 2007001898W WO 2008068429 A3 WO2008068429 A3 WO 2008068429A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
tnf
prevention
treatment
group
Prior art date
Application number
PCT/FR2007/001898
Other languages
English (en)
Other versions
WO2008068429A2 (fr
Inventor
Ryffel Valerie Quesniaux
Germain Puzo
Jerome Nigou
Martine Gilleron
Original Assignee
Centre Nat Rech Scient
Univ Orleans
Ryffel Valerie Quesniaux
Germain Puzo
Jerome Nigou
Martine Gilleron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Orleans, Ryffel Valerie Quesniaux, Germain Puzo, Jerome Nigou, Martine Gilleron filed Critical Centre Nat Rech Scient
Priority to US12/515,450 priority Critical patent/US20100048492A1/en
Priority to CA002670001A priority patent/CA2670001A1/fr
Priority to JP2009537673A priority patent/JP2010510298A/ja
Priority to EP07870304A priority patent/EP2091544A2/fr
Publication of WO2008068429A2 publication Critical patent/WO2008068429A2/fr
Publication of WO2008068429A3 publication Critical patent/WO2008068429A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant au moins un composé de formule (I) ou l'un de ses sels pharmaceutiquement acceptables dans laquelle R1, R2 et R3 sont indépendamment un hydrogène ou un groupement R7-CO- où R7 est un groupement alkyle, alcène ou alcyne linéaire, ramifié ou cyclique comprenant de 2 à 24 atomes de carbone; R4 est un atome d' hydrogène ou un groupement mannosyl substitué en position 6 par un résidu R6 choisi dans le groupe comprenant un atome d'hydrogène et un groupement R7-CO-; et R5 est choisi dans le groupe comprenant un atome hydrogène, un mono-, un di-, un tri-, un tétra- et un penta-mannosyl; ainsi que l'utilisation d'une telle composition pour la fabrication d'un médicament destiné à la prévention ou au traitement d'une maladie associée à la surexpression du TNF et/ou de l'IL-12 chez un sujet.
PCT/FR2007/001898 2006-11-20 2007-11-20 Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12 WO2008068429A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/515,450 US20100048492A1 (en) 2006-11-20 2007-11-20 Composition for the prevention and/or treatment of diseases associated with tnf and/or il-12 overexpression
CA002670001A CA2670001A1 (fr) 2006-11-20 2007-11-20 Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12
JP2009537673A JP2010510298A (ja) 2006-11-20 2007-11-20 Ｔｎｆおよびｉｌ−１２のうちの少なくとも一方の過剰発現に関連する疾病の予防または治療のための組成物
EP07870304A EP2091544A2 (fr) 2006-11-20 2007-11-20 Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0610136 2006-11-20
FR0610136A FR2908658B1 (fr) 2006-11-20 2006-11-20 Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12

Publications (2)

Publication Number Publication Date
WO2008068429A2 WO2008068429A2 (fr) 2008-06-12
WO2008068429A3 true WO2008068429A3 (fr) 2008-07-31

Family

ID=38008145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/001898 WO2008068429A2 (fr) 2006-11-20 2007-11-20 Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12

Country Status (6)

Country Link
US (1) US20100048492A1 (fr)
EP (1) EP2091544A2 (fr)
JP (1) JP2010510298A (fr)
CA (1) CA2670001A1 (fr)
FR (1) FR2908658B1 (fr)
WO (1) WO2008068429A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2931480B1 (fr) 2008-05-23 2016-04-01 Centre Nat Rech Scient Analogues synthetiques de phosphatidyl-myo-inositol mannosides pourvus d'une active inhibitrice de la reponse inflammatoire
WO2009143618A1 (fr) * 2008-05-28 2009-12-03 Sixtron Advanced Materials, Inc. Revêtement antireflet à base de carbure de silicium
US8766177B2 (en) 2010-10-11 2014-07-01 University Of North Texas Nanomanipulation coupled nanospray mass spectrometry (NMS)
ITRM20120473A1 (it) * 2012-10-04 2014-04-05 Consiglio Nazionale Ricerche Use of glycerophosphoinositols for the treatment of septic shock
AU2018262790B2 (en) 2017-05-05 2023-12-21 Huvepharma Functionalized saccharides as anti-inflammatory agents
EP3970799A4 (fr) * 2019-05-13 2023-05-24 Resonac Corporation Agent inhibiteur de la proliferation de cellules cancereuses ainsi que composition pour inhiber la proliferation de cellules cancereuse

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241376A1 (fr) * 1986-04-08 1987-10-14 Centre National De La Recherche Scientifique (Cnrs) Nouveaux liposomes à base de phosphatidylinositolmannosides, et compositions pharmaceutiques les contenant
WO1993015761A1 (fr) * 1992-02-13 1993-08-19 University College London Traitements du paludisme
WO2003011336A2 (fr) * 2001-08-03 2003-02-13 National Research Council Of Canada Proprietes adjuvantes d'un vaccin de liposomes formes a des temperatures elevees a partir de lipides polaires extractibles au chloroforme de mycobacterium bovis bcg
WO2006056783A2 (fr) * 2004-11-25 2006-06-01 Btg International Limited Phospholipides structures

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
GB9307491D0 (en) * 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
USRE40596E1 (en) * 1993-04-08 2008-12-02 Novartis Ag Rapamycin assay
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
FR2792205B1 (fr) * 1999-04-19 2001-07-27 Inst Nat Sante Rech Med Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
CA2440744C (fr) * 2001-03-15 2009-12-08 Seikagaku Corporation Agent de regulation d'expression d'il-12
EP1469007A1 (fr) * 2003-04-18 2004-10-20 Centre National De La Recherche Scientifique (Cnrs) Antigènes sulfoglycolipides, leur extraction de mycobacterium tuberculosis, et leur utilisation contre la tuberculose

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241376A1 (fr) * 1986-04-08 1987-10-14 Centre National De La Recherche Scientifique (Cnrs) Nouveaux liposomes à base de phosphatidylinositolmannosides, et compositions pharmaceutiques les contenant
WO1993015761A1 (fr) * 1992-02-13 1993-08-19 University College London Traitements du paludisme
WO2003011336A2 (fr) * 2001-08-03 2003-02-13 National Research Council Of Canada Proprietes adjuvantes d'un vaccin de liposomes formes a des temperatures elevees a partir de lipides polaires extractibles au chloroforme de mycobacterium bovis bcg
WO2006056783A2 (fr) * 2004-11-25 2006-06-01 Btg International Limited Phospholipides structures

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GILLERON M ET AL: "Acylation state of the phosphatidylinositol mannosides from Mycobacterium bovis bacillus Calmette Guérin and ability to induce granuloma and recruit natural killer T cells.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 14 SEP 2001, vol. 276, no. 37, 14 September 2001 (2001-09-14), pages 34896 - 34904, XP002434001, ISSN: 0021-9258 *
GILLERON MARTINE ET AL: "Acylation state of the phosphatidylinositol hexamannosides from Mycobacterium bovis bacillus Calmette Guerin and mycobacterium tuberculosis H37Rv and its implication in Toll-like receptor response.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 8 AUG 2003, vol. 278, no. 32, 8 August 2003 (2003-08-08), pages 29880 - 29889, XP002434002, ISSN: 0021-9258 *
KNUTSON K L ET AL: "Lipoarabinomannan of Mycobacterium tuberculosis promotes protein tyrosine dephosphorylation and inhibition of mitogen-activated protein kinase in human mononuclear phagocytes. Role of the Src homology 2 containing tyrosine phosphatase 1.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 2 JAN 1998, vol. 273, no. 1, 2 January 1998 (1998-01-02), pages 645 - 652, XP002434005, ISSN: 0021-9258 *
NIGOU J ET AL: "Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 JUN 2001, vol. 166, no. 12, 15 June 2001 (2001-06-15), pages 7477 - 7485, XP002434004, ISSN: 0022-1767 *
VIGNAL CÉCILE ET AL: "Lipomannans, but not lipoarabinomannans, purified from Mycobacterium chelonae and Mycobacterium kansasii induce TNF-alpha and IL-8 secretion by a CD14-toll-like receptor 2-dependent mechanism.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 AUG 2003, vol. 171, no. 4, 15 August 2003 (2003-08-15), pages 2014 - 2023, XP002434003, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
JP2010510298A (ja) 2010-04-02
FR2908658B1 (fr) 2011-11-11
CA2670001A1 (fr) 2008-06-12
US20100048492A1 (en) 2010-02-25
FR2908658A1 (fr) 2008-05-23
WO2008068429A2 (fr) 2008-06-12
EP2091544A2 (fr) 2009-08-26

Similar Documents

Publication Publication Date Title
WO2008012635A3 (fr) Dérivés d'amines utiles en tant qu'agents anticancéreux
WO2008108386A1 (fr) Composition pharmaceutique
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
WO2008068429A3 (fr) Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12
UA97351C2 (ru) Производная кумарина, имеющая противоопухолевую активность
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
WO2007060140A3 (fr) Inhibiteurs de diacylglycérol acyltransférase (dgat)
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
MX2010007375A (es) Nuevos derivados de lupano.
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
MX2009004096A (es) Metabolitos de talarozol.
WO2008006093A3 (fr) Modulateurs des récepteurs des estrogènes et utilisations de ceux-ci
WO2008108378A3 (fr) Dérivé bicyclique d'oxomorpholine
TW200634021A (en) 3,6-bicyclolides
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
RU2012110380A (ru) Новое производное 5-фторурацила
WO2005000863A3 (fr) Derives d'azalides 9a 6 11-4c-bicycliques
ATE279192T1 (de) Die verwendung eines benzimidazoles zur herstellung eines medikamentes zur krebsvorbeugung
WO2004087728A3 (fr) Derives 9a-azalide 6,11-3c-bicycliques
TW200745033A (en) Oxindole derivative as feeding control agent
MX2010002932A (es) Macrolidos de biarilo con puente en 6, 11.
WO2006065721A3 (fr) Bicyclolides de 11, 12-lactone
WO2008145524A3 (fr) Dérivés de pipéridine 4,4-disubstituée
WO2006129168A3 (fr) Derives bicycliques pour le traitement de croissance cellulaire anormale

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007870304

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2670001

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009537673

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07870304

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12515450

Country of ref document: US